Business Context and Reporting Period
Company: Alumis Inc. (ALMS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases. Its primary assets are two Tyrosine Kinase 2 (TYK2) inhibitors: envu (envudeucitinib) for plaque psoriasis (PsO) and systemic lupus erythematosus (SLE), and A-005, a CNS-penetrant inhibitor for neuroinflammatory diseases. In May 2025, the company completed the acquisition of ACELYRIN, Inc., adding the IGF-1R monoclonal antibody lonigutamab for Thyroid Eye Disease (TED) to its pipeline.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $24.1 million | $0 |
| Net Loss | $(243.3) million | $(294.2) million |
| Operating Expenses | $477.9 million | $300.8 million |
| Research & Development (R&D) | $386.0 million | $265.6 million |
| General & Administrative (G&A) | $91.9 million | $35.2 million |
| Cash, Cash Equivalents & Marketable Securities (Dec 31, 2025) | $308.5 million | $288.3 million |
| Accumulated Deficit (Dec 31, 2025) | $(901.9) million | $(658.6) million |
Note: Revenue in 2025 consists of $17.4 million in license revenue and $6.7 million in collaboration revenue from the Kaken Collaboration Agreement regarding envu in Japan.
Material Changes vs. Prior Period
- Revenue Generation: The company transitioned from zero revenue in 2024 to $24.1 million in 2025, driven by the March 2025 Kaken Collaboration Agreement.
- Operating Expenses: Total operating expenses increased 59% year-over-year. R&D expenses rose 45% due to accelerated clinical trial activities for envu (Phase 3 ONWARD trials) and the integration of ACELYRIN programs. G&A expenses increased 161%, largely due to transaction costs from the ACELYRIN Merger, severance costs, and increased public company compliance costs.
- Net Loss Improvement: Despite higher operating expenses, the net loss decreased by approximately 17% (from $294.2M to $243.3M). This improvement was primarily driven by a non-cash gain on bargain purchase of $187.9 million recognized upon the closing of the ACELYRIN Merger in May 2025.
- Acquisition: The acquisition of ACELYRIN added lonigutamab to the pipeline and resulted in the recognition of $51.0 million in acquired in-process research and development (IPR&D) intangible assets.
Guidance, Outlook, and Risks
Outlook and Milestones
- Envu (PsO): Positive topline results were reported in Q1 2026 for the Phase 3 ONWARD1 and ONWARD2 trials. The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.
- Envu (SLE): Topline results from the Phase 2b LUMUS trial are expected in the third quarter of 2026.
- A-005: Phase 1 results were reported in December 2024; the company is evaluating indications for a Phase 2 trial.
- Liquidity: As of December 31, 2025, the company held $308.5 million in cash and marketable securities. Following a public offering in January 2026 that raised $324.4 million, management believes funds are sufficient for at least 12 months from the filing date.
Key Risks and Contingencies
- Capital Requirements: The company has incurred substantial losses since inception and expects to continue doing so. It will require significant additional financing to fund operations and clinical trials. Failure to secure capital could force delays or termination of programs.
- Clinical Development Risk: There is no guarantee that envu, A-005, or lonigutamab will receive regulatory approval. The company previously discontinued a Phase 2a trial of envu in uveitis due to lack of efficacy.
- Legal Proceedings: The company assumed a purported federal securities class action lawsuit against ACELYRIN regarding disclosures related to a Phase 2b trial of izokibep. The motion to dismiss the second amended complaint remains pending as of the filing date.
- Regulatory and Pricing: The company faces risks related to FDA/EMA approval timelines, potential pricing pressures from government negotiations (e.g., Medicare Drug Price Negotiation Program), and changes in healthcare legislation.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $308.5M cash balance (plus $324.4M from Jan 2026 offering) against the projected burn rate for the envu NDA submission and SLE trial readouts.
- Envu Clinical Data: Review the full clinical study reports for the ONWARD1 and ONWARD2 trials to confirm the durability of the positive topline results and safety profile.
- ACELYRIN Integration: Assess the progress of integrating ACELYRIN's lonigutamab program and the status of the ongoing securities litigation assumed from the acquisition.
- Kaken Agreement Terms: Confirm the specific milestones and royalty rates under the Kaken Collaboration Agreement to understand future revenue potential.
- Regulatory Strategy: Monitor FDA feedback on the planned NDA submission for envu in PsO scheduled for H2 2026.